It’s crazy isn’t it. Acadia has now outperformed Neuren YTD whilst announcing a failed phase 3 trial In March and being the initial target of the short report.
Neuren (as we know) announced 3 consecutive successful phase 2 results in the same time frame, yet we have still underperformed compared to ACAD relatively. The logic that this is due to Daybue sales or some other external factor (US policy) isn’t a convincing explanation IMO.
It could be as simple as a large entity sellling where there is no buying interest. Again - surely you’d at least space it out?
But it could be a way to make a stock based offer more economical for Acadia and avoid them needing to pay Neuren 100m next quarter and more in future on Daybue, whilst bolstering their pipeline with 2591
Acadia has already stated they are interested in “business opportunities” and acquisitions including on their most recent conference call.
NEU Price at posting:
$12.36 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)